| ALLOPURINOL; LESINURAD | None | ||
| 200MG;200MG, 300MG;200MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| DUZALLO, a combination of lesinurad, a URAT1 inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone. | |||
|
Yes
| |||
| DUZALLO | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||
| ********* *** ************ *** ******* ** *** | ********* *** ************ *** ******* ** *** | ********* *** ************ *** ******* ** *** | *********** ***** ** *-(*-*****-*-(*-*********************-*-**)-**-*,*,*-*******-*-******)****** **** *** **** ******* | ********* *** ************ *** ******* ** *** | ********* ** **** *** ************* | *********** ***** ** *-(*-*****-*-(*-*********************-*-**)-**-*,*,*-*******-*-******)****** **** *** **** ******* | ********* *** ************ *** ******* ** *** | *-(*-*****-*-(*-*********************-*-**)-**-*,*,*-*******-*-******)****** **** *** ****** ***** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|